AstraZeneca PLC
AZN: XLON (GBR)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
GBX 26,875.00 | Ymmv | Tztdhmkc |
AstraZeneca: Tagrisso Competitive Threat Looks Manageable While New Cancer Data Supports Dato-DXd
We are holding firm to our AstraZeneca fair value estimate following clinical updates from the European Society of Medical Oncology (ESMO) annual meeting. Overall, the innovation updates at the conference help support Astra’s current drugs and next generation of drugs, reinforcing the firm’s wide moat.